AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03139604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.
Study NCT03073252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Protein
Description: Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl
Study NCT03073252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIgh Protein
Description: Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl
Study NCT02206477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Sulfoxide
Study NCT02206477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Study NCT06237933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced intervention via social networking site (SNS)
Description: We plan to organize a private Facebook group serve as platform to provide the intervention content. To ensure confidentiality, this Facebook group is completely private and the group member is invited only by study staff. The participants of intervention group received information about the private Facebook group and privacy settings and were instructed to join the Facebook group. The intervention comprises three parts. Doctor patient interaction: The interventionist (physicians and dietitians) act as health coach will provide evidence-based topics related to weight loss on Facebook discussion board every two weeks
Study NCT06237933 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard intervention
Description: In the session, the participants are instructed by an interventionist to have a reduced calorie diet and regular physical activity. Calorie intake was prescribed based on baseline weight at 1200 kcal/d for individuals who weighed less than 90 kg, 1500 kcal/d for those who weighed 90 to less than 115 kg, and 1800 kcal/d for those who weighed 115kg or more. The interventionist will give each participants dietary recommendation and sample meal plans are provided to facilitate adoption. The interventionist will prescribe non-supervised moderate-to-vigorous physical activity to participants. Participants should start moderate-to-vigorous physical activity at 100 minutes per week and increased at 4-week intervals until a prescription of 300 minutes per week was achieved
Study NCT00902070 — intervention group
Intervention type: DRUG
Intervention: Rocuronium
Description: Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
Study NCT02417753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
Study NCT01657162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Alendronate is a bisphosphonate drug that prevents bone resorption by osteoclast and is used for the treatment of osteoporosis.
Study NCT04625335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Massage Protocol
Description: Participants did not receive therapeutic massage prior to completing the Cold Pressor Test.
Study NCT02523703 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: glutamate and aspartate
Study NCT02509832 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cooling + PCI
Description: Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI)
Study NCT04625335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic Therapeutic Massage
Description: Participants received a 5 minute prophylactic therapeutic massage prior to completing the Cold Pressor Test. The massage was completed distally-to-proximally in the following order: superficial strokes to the entire forearm, deep strokes to the entire forearm, one-handed palmar kneading of the entire forearm with participant's forearm stabilized by the massager's the other hand, bilateral thumb kneading of the forearm in strips until the entire forearm was addressed, bilateral transverse thumb motions over palmar surface of the hand, single thumb kneading of thenar and hypothenar eminences simultaneously, bilateral thumb kneading to the dorsum of hand, deep stroking to the entire forearm, and superficial stroking to the entire forearm.
Study NCT00901342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
Study NCT04238377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate Ganglion Block
Description: Using US with a linear array transduce, subfascial-C6- Stellate Ganglion Block. Patients will be supine with the neck slightly hyper- extended. After aseptic preparation of the skin, the transducer is placed on the neck to enable cross sectional visualization of anatomical structures at the level of C6. The carotid artery, internal jugular vein, thyroid gland, trachea, longus colli covered with the prevertebral fascia, root of C6, and transverse process of C6 are all visualized. The transducer will then gently be pressed between the carotid artery and trachea to retract the carotid artery laterally and to position the transducer close to the longus colli.~A 1.0-inch, 25-gauge long-bevel needle were paratracheal inserted toward the middle of the longus colli. The endpoint for injection were the ultrasound image demonstrating the tip of needle penetrating the prevertebral fascia in the longus colli. After negative aspiration, 5 mL of 0.5% bupivacaine was injected
Study NCT04238377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multimodal Analgesia
Description: Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg
Study NCT04238377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Analgesia
Description: Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg
Study NCT02245165 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg/kg IV
Study NCT02245165 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: saline
Study NCT01559805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Choices
Description: A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
Study NCT01559805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Cognitive Counseling
Description: A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
Study NCT01884948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven™
Study NCT03497871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMan system
Description: The HeartMan system uses wristband sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
Study NCT04361422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin Only Product in Oral Dose Form
Description: assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.
Study NCT04361422 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Isotretinoin Only Product in Oral Dose Form
Description: assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.
Study NCT01209403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-infusion
Description: Continuous iv infusion of glucose
Study NCT01209403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-insulin infusion
Description: Continuous iv infusion of glucose and shortlasting
Study NCT03003442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supradyn® Energy 3RDA
Description: Multivitamin/mineral containing co-Q10
Study NCT03003442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04504110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT
Description: Patients with epithelial ovarian cancer who are scheduled for surgical intervention will undergo a comparative 68Ga-FAPI-04 and 18F-FDG PET/CT study before the surgery.
Study NCT03988153 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Probiotic Milk Formula
Description: Drink 200 mL of PMF for 10 weeks and followed by 2 weeks of follow up period for monitor any adverse effect
Study NCT03988153 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Milk Formula
Description: Drink 200 mL of PMF for 10 weeks and followed by 2 weeks of follow up period for monitor any adverse effect
Study NCT01575171 — intervention group
Intervention type: BEHAVIORAL
Intervention: Nudge
Description: Behavioral economics recognizes that individuals often are not fully rational in the purely economic sense, but are subject to the influence of various social, environmental and cognitive factors in their decision making. And, one can take advantage of these findings to nudge individuals, in our case physicians, towards more optimal choices. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines.
Study NCT00642226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Grid Laser
Description: ETDRS Grid Laser
Study NCT00642226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy and 20 mg triamcinolone
Description: Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
Study NCT01023594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic stent
Description: Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.
Study NCT00916552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 40.000 IU/ml epoetin alfa is administered as intravenous infusions over 15 min weekly for 8 weeks.
Study NCT01171157 — intervention group
Intervention type: OTHER
Intervention: Routine sample collection
Description: Collection of routine nasal/throat swab samples
Study NCT03847961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoperfusion with cytokine adsorption column (CA330)
Description: Hemoperfusion treatments are performed using a perfusion machine via centrally inserted standard dialysis catheters at a prescribed blood flow rate of 100-300ml/min. In the beginning, lower flow rate is recommended, if there is no discomfort, then gradually increases. Each patient received 2 hemoperfusion treatments within 24 hours with a target duration for each treatment of 120-180 minutes (minimum of 120 minutes). The shorter the interval between the two hemoperfusion is, the better. It is suggested that the second hemoperfusion be performed within 0-5 hours after the first one.
Study NCT02616783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Study NCT02616783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300 mg tablet administered orally once daily
Study NCT02616783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC
Description: 200 mg capsule administered orally once daily
Study NCT02616783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg tablet administered orally once daily
Study NCT02616783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC
Description: Tablet administered orally
Study NCT02616783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Third agent
Description: Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG
Study NCT03663296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airway Ex App
Description: 30 minutes of self-directed learning and practice using the mobile application
Study NCT01307813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overstitch Endoscopic Suturing System
Description: Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.~Patients will already require resection of segments of colon for treatment of benign or malignant disease and this will therefore be a treat and resect model
Study NCT01491425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS//LT-CAGE® Device
Description: LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
Study NCT01491425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Bone//LT-CAGE® Device
Description: LT-CAGE® device with autogenous bone taken from the iliac crest.
Study NCT01634646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lyzme5
Description: Dietary Supplement (or placebo):~Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.).~Week one:~A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast;~Week two:~Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal;~Week three through the end of the study:~Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day.
Study NCT04630223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: endocan in umbilical cord blood
Description: After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.
Study NCT02709148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: DBS
Study NCT00955799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane mesylate
Description: Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
Study NCT00955799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind treatment period of 29 weeks placebo
Study NCT02664077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
Study NCT02664077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
Study NCT03686553 — intervention group
Intervention type: OTHER
Intervention: laboratory-based data collection
Description: laboratory-based surveillance of SSI
Study NCT03564470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide will be administrated at dose of 10mg/day in chidamide arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for chidamide arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (chidamide, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
Study NCT03564470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib will be administrated at a dose of 100mg/day in dasatinib arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for dasatinib arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (dasatinib, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (dasatinib, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
Study NCT01309321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perinatal Handwashing Promotion
Description: Pregnancy may serve as a unique opportunity to improve maternal handwashing behavior more deeply and sustainably than a handwashing promotion intervention at a different time. Primiparous women will receive an intensive handwashing promotion program delivered at 3 in-home visits between one month prenatal and 1 week post natal. The program will promote handwashing benefits, provide hardware to reduce barriers to handwashing, and educate mothers about the critical times for handwashing. Mothers will also receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
Study NCT01309321 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neonatal Health Promotion
Description: Mothers will receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
Study NCT00072410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90Y-hu3S193
Description: Patients received a single dose of 10 mg of hu3S193 radiolabeled with the intended dose (mCi) of 90Y.
Study NCT00072410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 111In-hu3S193
Description: Patients received a single dose of 5 mCi 111In-hu3S193 together with the 90Y-hu3S193.
Study NCT01706367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine
Description: 0.5 mL IM injection
Study NCT01706367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine +adjuvant
Description: 0.5 mL IM injection
Study NCT02509832 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PCI only
Description: Standard of Care for PCI
Study NCT01205854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Standardized ultrasonographic assessment of 32 joints, assessed for both grey scale synovitis and power doppler signal, at each visit. Dose escalations based on DAS response in combination with change in US score. All joints with US Power Doppler signal are targets for intra articular injections.
Study NCT02564380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02564380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo